JUL 29, 2020 9:00 AM EDT

Impedance-based assay to evaluate potency of immunotherapy products

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Analytical Development Scientist, Cell and Gene Therapy Catapult
    Biography
      Juan Miguel Sánchez Nieto studied Biotechnology at Francisco de Vitoria University (Madrid, Spain). He moved to London in 2010 where he did an MSc in Molecular Medicine at UCL. Juan Miguel continued his scientific career at Imperial College London, where he completed a PhD in Developmental and Stem Cell Biology. His research was focused on understanding the differential sensitivity to cell death observed at the onset of embryonic stem cell differentiation. He joined Cell and Gene Therapy Catapult´s Industrialisation team in 2017 as an Analytical Development Scientist. Juan Miguel has been involved in the experimental design and execution of multiple projects related to the development of novel analytics for viral vector, stem cell and somatic cell therapies. Juan Miguel has been leading Cell and Gene Therapy Catapult's efforts in the development and qualification of in vitro potency assays for TCR and CAR-T cell-based immunotherapies.

    Abstract

    Advances in genetic engineering have improved specificity, safety and potency of T-cell receptor (TCR) and Chimeric Antigen Receptor (CAR-T) based therapies for solid and non-solid tumours. These developments have allowed the manufacturing and commercialisation of these immunotherapy ATPMs (advanced therapy medicinal products). However, there is a current need to develop more robust product release assays to shorten product release time, including methods to ensure the identity, safety or potency of the product. Current methodologies to evaluate product potency require cell labelling, are labour intensive and only provide information about product’s specific cytotoxic effect at one selected time-point. The xCELLigence platform overcomes these limitations by measuring electrical impedance over time. In this presentation we will discuss how to develop and qualify the use of a high-throughput impedance-based system to measure T-cell cytotoxicity for both TCR or CAR-T approaches using either suspension or adherent target cell lines.


    Show Resources
    You May Also Like
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    MAR 11, 2020 6:00 AM PDT
    C.E. CREDITS
    MAR 11, 2020 6:00 AM PDT
    The locomotion of humans and other animals requires a seamless flow of information from sensory modalities all the way to the motor periphery. As such, locomotion is an excellent system for...
    APR 30, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 30, 2020 8:00 AM PDT
    DATE:April 30, 2020 TIME: 8AM PT, 11AM ET, 4PM BST, 5PM CEST Cytokinesis is the physical separation of two cells that occurs after the completion of mitosis. The mechanism underlying it is v...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    AUG 26, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    AUG 26, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: August 26, 2020 TIME: 8:00 am PDT The host immune "recognition" of cancer forms the basis of modern tumor immmunotherapy, a highly targeted treatment option with the demonstr...
    Loading Comments...
    Show Resources